tC = malignant
Malignant, N0/N1, HR negative and Her2Neu negative 6 Malignant, T2-T4, HR positive, Her2Neu negative with chemotherapy (aged ≤50 years) 7
Malignant, T2-T4, HR positive. Her2Neu negative and chemotherapy naïve (aged >50years) 8
Malignant, HR positive and Her2Neu positive 9 Metastatic breast cancer, T1a-T1b, N0, HR positive and Her2Neu negative (aged ≤50 years) 10
Metastatic breast cancer, N+, HR positive and Her2Neu negative (aged > 50 years) 11
Metastatic breast cancer, HR negative and Her2Neu negative 12 'N' = nodal stage. 'HR' = hormonal receptor status. 'Her2Neu' = Her2Neu receptor status. Of the 6 stable expressed miRs identified in the micro-array data all except hsa-miR-188-5p could be measured reliably by RT-qPCR in the validation set. As the median value of the 25 miR panel with an M-value of 0.50 versus 0.60 for the remaining 5-miR reference miR panel was identified as the most stable marker for our analysis, we normalized our data on the median level of all 25 miRs that could be quantified reliably. Also when analyzed separately for benign and malignant/metastatic with NormFinder, the median of the 25 miR panel had the lowest variability.
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